Current treatments for Parkinson's still only provide symptomatic relief but Bayer AG is hopeful that a couple of its cell and gene therapies being developed by its wholly owned subsidiaries BlueRock Therapeutics LP and Asklepios BioPharmaceutical, Inc. could potentially offer a paradigm shift in tackling the disease.
Bayer's Bets In Parkinson's Start To Bear Fruit
The German major is kicking off Phase II trials for a cell therapy and a gene therapy that could be gamechangers for the progressive neurodegenerative disorder that affects more than 10 million people worldwide.
